Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Live Attenuated Vaccine in Pediatric Patients Receiving Immunosuppressants
jRCTs031190140Completed
- Start
- Jun 2016
- Modality
- Live Attenuated Vaccines → Live Vaccines → Prophylactic Vaccines → Vaccines & Immunotherapeutics, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
Open-label, single-arm trial of measles vaccine, rubella vaccine, live, measles and rubella vaccine (live), Varicella vaccine live attenuated (Shenzhen Mellow Hope) and mumps live attenuated vaccine in measles, rubella, chickenpox and 1 more. Primary endpoints: Positive rate of each viral IgG 2–6 months after vaccination and Content and frequency of severe adverse events. Started Jun 2016; status: completed.
02
Drugs
measles vaccinerubella vaccine, livemeasles and rubella vaccine (live)Varicella vaccine live attenuated (Shenzhen Mellow Hope)mumps live attenuated vaccine
03
Conditions
measlesrubellachickenpoxmumps
Beyond the preview
Go deeper on jRCTs031190140.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCTs031190140.